China
30 videos · updated daily
50:04 China's Biotech Rise and Clinical Trials
Tim Scott, President and CEO of Biocom, shares observations from a biotech delegation to Shanghai, including how China's investigator-initiated trials work, trial-ready cohorts, licensing and what it means for U.S. competition, for the Making Medicine Podcast.
17:28 Big Pharma Needs New Drugs. China Has Them
Bloomberg reporters Amber Tong and Robert Langreth explain why US drugmakers are increasingly licensing drugs discovered, tested and developed in Chinese labs, and what it means for US biotech, on Bloomberg's Big Take Asia.
40:33 China Biotech: From Fast Follower to First in Class
At the 2026 World Medical Innovation Forum, a panel with Hui Feng of Allink, Judith Li of Lilly Asia Ventures, Jianguo Michael Yin of BioBAY and Weian Zhao of Aureka Biotechnologies discusses China's shift from generics to novel drugs and global development.
12:00 Tess Cameron, RA Capital, on China Biopharma Going Global
Tess Cameron, Managing Director at RA Capital, discusses how the firm views cross-border assets, clinical trial execution in China and global biotech dealmaking, in PharmCube's BIO & Beyond series.
6:15 Goldman Sachs' Salveen Richter on Pharma and China Assets
On CNBC, Salveen Richter, Goldman Sachs lead U.S. biotech analyst, discusses biotech innovation in China and why, in October 2026, large biopharma companies were looking at Chinese drug assets.
2:27 Exclusive: Death of Girl in Chinese Gene-Editing Trial Was Never Made Public
Meagan Cantwell, a video producer at Science, reports on the death of a girl in a Chinese gene-editing trial that was never made public.
37:40 Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation
Jayson Slotnik, JD, MPH, of Health Policy Strategies and Steve Usdin of BioCentury discuss the future of the FDA, clinical trial efficiency, and the forces shaping biopharmaceutical innovation.
37:27 Rep. Scott Peters on the Pill Penalty, PBMs and China
Rep. Scott Peters of San Diego discusses ending the Inflation Reduction Act's "pill penalty", PBM reform, FDA modernization and China's rise in biotechnology as a strategic concern, on the Making Medicine Podcast.
52:08 The Biotech Race Between the U.S. and China
A Washington Post Intelligence briefing with WPI analyst Rebecca Adams, Thomas J. Bollyky of the Council on Foreign Relations and Jocelyn Ulrich of PhRMA examines China's growing share of the global drug pipeline and its faster, cheaper clinical trials.
59:52 Earli's Cyriac Roeding on Cancer, China and Biotech Funding
Earli co-founder and CEO Cyriac Roeding discusses the company's in vivo approach to cancer, China's 2026-2030 biotech plan and how US funding cycles affect early-stage drug development, on Life Science Connect's Business of Biotech.
25:46 Senator Todd Young on Biotech, China and FDA Reform
Senator Todd Young discusses the risks of relying on China for critical biotech inputs, why FDA speed and regulatory clarity matter, drug pricing and US biotech competitiveness, on the Making Medicine Podcast.
19:23 Why Cancer Patients Are Flying to China for Treatment
BBC World Service's Asia Specific examines why a growing number of cancer patients travel to China for CAR-T cell therapy that can be faster, cheaper and more accessible than in many Western countries.
12:27 Why Are Clinical Trials Moving So Fast in China? - Voices of SCOPE
Gary Ma, President and CEO of Taimei Technology US, discusses what drives the speed of clinical trials in China, including streamlined processes, digital tools, CRC support for investigators and hospital networks linking patients to trials, for SCOPE 365.
7:40 China's Innovation and the Future of Pharma
Eric Tse, CEO of Sino Biopharmaceutical, discusses China's accelerating pharmaceutical innovation, global companies investing in China and the role of AI in speeding up research and clinical trials, at the Summer Davos Forum, for CGTN.
4:55 McKinsey's Wang Jin on China's Biopharma Boom
Wang Jin, Senior Partner and leader of McKinsey & Company's Life Sciences Practice in China, discusses the growth of China's biopharmaceutical sector and how its homegrown companies are becoming competitive globally, for CGTN Europe.
5:00 Akeso's Michelle Xia and the Drug That Beat Merck's in a Trial
Forbes profiles Michelle Xia, who founded a biotech company in China after working at U.S. pharmaceutical firms, and whose cancer drug outperformed the world's best-selling drug in a trial last year.
19:35 How China Is Shaking Up the World of Pharmaceuticals
CNA Senior Correspondent Tan Yew Guan explores China's biotech ambitions, how its drug innovation has outpaced the rest of the world, why Chinese biotechs license out their drugs, and its push to make treatments accessible and affordable.
5:52 Timelines: Clinical Trials in China and Japan
Michael Young of biomedwoRx Life Sciences Consulting and Sarah Lieber, head of North American regulatory affairs at Sanofi, discuss how long it takes to start a clinical trial in China and the Asia-Pacific region, in July 2022.
12:11 China and the U.S. in New Drug Clinical Trials
The Making Medicine podcast looks at data showing China had overtaken the United States in new drug clinical trials by March 2026, alongside the reauthorisation of the SBIR and STTR small-business research programmes.
10:31 Drug Law Earthquake: Will BioSecure Act Shift $$$ From China to India?
ibaji Biswas, ED & CFO, Syngene International, as US considers the Biosecure Act that aims to reduce reliance on Chinese contract drug manufacturers & research organizations.
24:25 John Gutierrez on Investors, Washington and China Biotech
Life sciences investor John Gutierrez describes meeting the National Security Commission on Emerging Biotechnology and Congress, and how competition from China, drug pricing proposals and FDA uncertainty shape early-stage investment, on the Making Medicine Podcast.
1:21:21 China's Early-Stage Clinical Development and Global R&D
A BioVerse webinar panel including Grace Wang, Leon Tang, Yong-Jiang Hei and Tess Cameron examines China's early-stage clinical development capabilities, China-to-West deal flow, CAR-T case studies and investigator-initiated trials.
35:29 Protecting US Biotech From Chinese Competition: NSCEB
Caitlin Frazer, Executive Director of the National Security Commission on Emerging Biotechnology, discusses its proposals on China's rise in biotech and the role of policy in supporting US biotech, with Endpoints News reporters.
43:43 China NMPA and FDA Imaging Endpoint Guidelines
In February 2021, Median Technologies CMO Yan Liu, on the expert panel behind China NMPA's then-draft guidelines on imaging endpoints in anti-tumour drug trials, and QA head Faisel Jobrani compare them with FDA guidance.